AgilityBio, a division of BioImagene, and Advinus Therapeutics, have teamed up to bolt on imaging services to the latter’s existing preclinical development offering.
Advinus, which provides preclinical development services to the global pharmaceutical and biotechnology industries, will combine its existing platform with AgilityBio’s imaging capabilities to create a suite of solutions for cancer diagnosis and research for preclinical development.
The firms said that while image data is a critical component for decision making in preclinical toxicology studies often in the drug discovery and development fields, extracting meaningful information and knowledge from image data is still carried out manually in a time consuming and hence inefficient and expensive process.
The companies explained that the partnership will offer industrial customers a high value solution for performing toxicology studies and rapid image management and processing, creating novel opportunities for global collaboration.
Speaking at the Society of Toxicologic Pathology annual Meeting in Bangalore, India Nimish Vachharajani, vice president of Advinus, said that: “This alliance brings together the world-class preclinical development services of Advinus and the cutting-edge technology of AgilityBio.
“In particular for our international clients, digitalization of slides from toxicology studies will offer an affordable alternative to reduce travel time and costs for peer-reviews,” he added.
These thoughts were echoed by BioImagene CEO Ajit Singh who predicted an "acceleration of drug development and numerous opportunities for Indian pathologists to integrate with the global drug discovery markets."
Singh went on to say that: “We foresee a significantly improved work flow in the laboratory and seamless execution of preclinical projects, which will ultimately save veterinary pathologists a lot of time.”